Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Dr Lal PathLabs Q4 Results: Profit slips 15% despite strong revenue growth; ₹4 dividend announced
Dr Lal PathLabs Q4: net profit down 15.2 percent to 131.3 crore, revenue up 16.6 percent to 702.7 crore, margins narrow, board proposes 4 rupee final dividend per share
India ready to meet 270 GW peak power demand this summer, says Manohar Lal
India is ready for this summer's peak power demand of 270 GW. The nation's power infrastructure is robust. Future demand will rise with AI, data centers, and electric vehicles. Transmission lines are expanding significantly. This ensures reliable power supply for growing needs.
Lorenzini Apparels Ltd leads losers in 'B' group
SEPC Ltd, Archidply Decor Ltd, Panorama Studios International Ltd and MRC Agrotech Ltd are among the other losers in the BSE's 'B' group today, 13 March 2026.
NTPC pays power ministry Rs 2,666.58 cr in second dividend for FY26
A ceremonial cheque was handed over to Minister of Power Manohar Lal by company officials on February 27, NTPC said in a statement.
Momentum Stocks: Dr Lal PathLabs, JHS Svendgaard, Dar Credit rally on sheer momentum
A few stocks saw sharp intraday moves and hit upper circuits. California Software, Omax Autos, Axiscades Technologies, Sterlite Technologies, DCM Shriram Fin were locked in the upper band, reflecting strong demand and limited supply—often a sign of bullish near-term sentiment.
Trade Spotlight: How should you trade Gland Pharma, Dr Lal PathLabs, Himadri Speciality Chemical, Axis Bank, JSW Steel, and others on June 12?
The market needs to surpass and sustain above its short-term moving averages for a further uptrend; until then, consolidation may continue. Below are some short-term trading ideas to consider.
Buy Dr Lal Pathlabs; target of Rs 1740: Emkay Global Financial
Emkay Global Financial is bullish on Dr Lal Pathlabs has recommended buy rating on the stock with a target price of Rs 1740 in its research report dated Jun 09, 2026.